G1 Therapeutics Enters Definitive Merger Agreement With Pharmacosmos Therapeutics Inc.
August 08, 2024
August 08, 2024
BOSTON, Massachusetts, Aug. 8 -- Ropes and Gray, a law firm, issued the following news on Aug. 7, 2024:
Ropes & Gray represented G1 Therapeutics, Inc., a commercial-stage oncology company in a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire G1 Therapeutics for a total equity value of approximately $405 million. The transaction was announced in an Aug. 7 press release (https://investor.g1therapeuti . . .
Ropes & Gray represented G1 Therapeutics, Inc., a commercial-stage oncology company in a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire G1 Therapeutics for a total equity value of approximately $405 million. The transaction was announced in an Aug. 7 press release (https://investor.g1therapeuti . . .